Summarized by Masters of Longevity from Retro Biosciences.
The company announced an initial financing close led by 4P Capital at a $1.8 billion pre-money valuation. The amount raised was not disclosed.
Key Takeaways
- The $1.8 billion figure is a pre-money valuation, not the amount raised.
- Proceeds support aging-focused drug discovery, cell therapy and tissue reprogramming.
- RTR242 was in Phase 1 testing; the announcement did not establish clinical efficacy.
